How does methotrexate affect the immune system?
Methotrexate is a widely used medication that acts as an immunosuppressant, specifically a disease-modifying antirheumatic drug (DMARD). [1] It is commonly used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and certain types of cancer.
What is the mechanism of methotrexate's immunosuppressive action?
When methotrexate is administered, it works by inhibiting the replication and proliferation of rapidly dividing cells, including activated T and B lymphocytes, which are key components of the immune system. [2] By blocking the action of folate, a crucial component for DNA synthesis, methotrexate disrupts the normal functioning of the immune system, preventing the overproduction of inflammatory mediators.
How does methotrexate's immunosuppressive action impact the immune response?
Research suggests that methotrexate's immunosuppressive effect is mainly attributed to its ability to reduce the activation and proliferation of T cells, as well as its inhibitory effect on the production of pro-inflammatory cytokines. [3] This leads to a decrease in the overall immune response, reducing inflammation and tissue damage.
What are the potential side effects of methotrexate-related immunosuppression?
As methotrexate is metabolized, it can lead to a decrease in lymphocyte count, making patients more susceptible to infections, such as those caused by opportunistic pathogens. [4] Additionally, long-term use of methotrexate can lead to a decrease in B-cell counts, increasing the risk of infections.
Why is monitoring the immune system important when using methotrexate?
Regular monitoring of blood counts and lymphocyte levels is crucial when using methotrexate. This allows for early detection of potential side effects, such as infections or myelosuppression, enabling timely intervention and dose adjustments as needed.
Who should consider methotrexate treatment under medical supervision?
Methotrexate should be used under medical supervision, especially for patients with autoimmune diseases, cancer, or those with compromised immune systems, due to the potential risks associated with immunosuppression.
References:
[1] https://www.drugpatentwatch.com/drugs/methotrexate
[2] Zhang J, et al. (2013). Mechanism of action of methotrexate in rheumatoid arthritis. Nat Rev Rheumatol, 9(10), 576-586.
[3] Taylor PC, et al. (2016). The mechanism of action of methotrexate in autoimmune disease. Biochem Soc Trans, 44(4), 1045-1051.
[4] https://www.ncbi.nlm.nih.gov/pubmed/21364651